|
Michael B. Atkins, MD, is currently deputy director of the division of hematology/oncology at Beth Israel Deaconess Medical Center; director of the cancer clinical trials office; director of the cutaneous oncology program; director of the biologic therapy program; director of clinical research at Beth Israel Deaconess Cancer Center; and leader of the renal cancer program at Dana Farber/Harvard Cancer Center. He is also a professor of medicine at the Harvard Medical School.
Dr. Atkins received his medical education at Tufts University School of Medicine and postgraduate training at the New England Medical Cancer Center Hospital. Following his training, Dr. Atkins held several academic and hospital appointments at the New England Medical Cancer Center Hospital until 1997. Since 1997, Dr. Atkins has developed and led several programs at the Beth Israel Deaconess Medical Center in Boston and the Dana Farber/Harvard Cancer Center (DF/HCC), most notably in cutaneous oncology, renal cancer and clinical trials. Dr. Atkins’ major research interests are immunotherapy of malignancy, with specific emphasis on the use of cytokines such as interleukin 2, and interferon and vaccines, treatment of melanoma and renal cell carcinoma, predictive markers for response to biologic therapy, and antiangiogenic and targeted therapies. His research work has been funded by the National Cancer Institute, various foundations and several pharmaceutical companies.
Dr. Atkins is director of the DF/HCC Kidney Cancer Specialized Programs of Research Excellence (SPORE) grant and co Principal investigator of the DF/HCC Skin Cancer SPORE. He has also been invited to deliver special lectures at several venues, such as the annual meeting of the American Society of Clinical Oncology (ASCO), and to author special reviews. He has been on the editorial boards of several journals, including Cancer, Journal of Translational Medicine, Kidney Cancer Journal, Journal of Clinical Oncology and Journal of Immunotherapy (associate editor). Dr. Atkins has also been on the advisory boards of several pharmaceutical companies, including AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Pfizer, Schering, Wilex and Wyeth. Dr. Atkins has served on the advisory board of the Melanoma Foundation of New England, the Melanoma Research Foundation and the Kidney Cancer Association, the program committees for ASCO and American Association for Cancer Research and is past president of the International Society for Biological Therapy of Cancer. | 